相关实验视频

Updated: Feb 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

费布里病的免疫性:当前问题,应对策略和未来方向

Andrea Matucci¹, Sandro Feriozzi², Elena Biagini³

¹Immunoallergology Unit, Careggi University Hospital, 50134 Florence, Italy.

|February 27, 2026

概括

抗药抗体 (ADA) 可以降低酶替代疗法 (ERT) 在法布里病 (FD) 的有效性. 阿加尔酶-α表现出比阿加尔酶-β更好的耐受性和更少的ADA,有助于个性化FD治疗策略.

科学领域:

遗传学和罕见疾病.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

法布里病 (FD) 是一种由GLA基因突变引起的X链 lysosomal储存障碍,导致α-galactosidase A 缺乏.
使用agalsidase-α或agalsidase-β的酶替代疗法 (ERT) 是标准的,但抗药抗体 (ADA) 可以阻碍有效性和安全性.
ADA的形成对长期的FD管理构成挑战,影响临床结果和治疗坚持.

研究的目的:

审查免疫性,特别是ADA对法布里病ERT的影响.
分析当前在FD患者中管理ADA相关问题的策略.
为了比较agalsidase-α和agalsidase-β的免疫特征.

主要方法:

关于FD免疫性和ERT的最近研究的文献综述.
分析ADA的形成,持久性和临床影响.
基于生产,药理动力学,药理动力学和免疫性对阿加尔西达α和阿加尔西达β的比较评估.

主要成果:

ADAs可以增加药物清除,形成免疫复合体,引起炎症,并触发输液反应,使FD复杂化.
与agalsidase-β相比,agalsidase-α具有更有利的耐受性概况,ADA的发病率较低.
尽管有效性重叠,但生产中的差异对两种ERT剂都有明显的免疫学影响.

结论:

个性化的FD治疗需要根据个体患者的免疫风险选择合适的ERT.
监测原始患者的ADA,并将血清学数据与临床模式关联起来,对于最佳管理至关重要.
解决免疫性是提高ERT有效性和改善法布里病患者治疗结果的关键.

关键词:

律师助理律师 (ADAs) 是一个职责.现在,我们来看一下ETT ERT.费布里病是什么意思费布里病是什么意思抗阿加尔西达抗体的抗体.酶替代疗法是一种酶替代疗法.免疫性免疫性免疫性与输液相关的反应.

更多相关视频

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.